Company news: Merck, Novo Nordisk

Share this article:
Merck is seeking to trim its Cork staff by about 90 employees, reported RTE News, which also noted the company hopes to cut those jobs through “voluntary redundancies” over the next six months. RTE said reduced production of Interferon is behind the proposed slimdown.

Novo Nordisk is hiring about 1,000 people to tackle the diabetes marketplace in emerging markets like Vietnam, reported Bloomberg Wednesday. Bloomberg said the company wants to expand in areas including Egypt and Ukraine and expects to bring on the new staff over 24 months.

The Epilepsy Foundation (founded in 1968) and the Epilepsy Therapy Project (established in 2002) announced Thursday they will soon be known as the Epilepsy Foundation. Integration of the two non-profits is expected to be completed by January 2013. The two groups said in a joint statement that they have helped fund “42 of the 85 known drugs and devices in active development.”

The invite-only healthcare resource HealthyBegins.org announced its first invitations to the beta-stage social site have been sent out. The site's goal is to crowdsource information about factors that can have an impact on patient health -- for example, environmental and social dynamics -- and how to address them. “Clinicians and students who use this new resource will spur a transformation in the way we provide healthcare by helping improve health where it begins,” founder and CEO Rishi Manchanda said in a statement.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.